BLA 761349 · Novartis Pharms Corp
Cosentyx
Secukinumab · Injection · Interleukin-17A Antagonist
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 6, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
207
101 Phase 3, 16 recruiting
FAERS reports
161,904
65,379 serious, 9,022 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 15, 2026.
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. ( 1.2 ) active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. ( 1.3 ) active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. ( 1.4 ) active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. ( 1.5 ) moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. ( 1.6 ) 1.1 Moderate to Severe Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. 1.2 Active Psoriatic Arthritis COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. 1.3 Active Ankylosing Spondylitis COSENTYX is indicated for the treatment of active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. 1.4 Active Non-Radiographic Axial Spondyloarthritis COSENTYX is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation. 1.5 Active Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. 1.6 Moderate to Severe Hidradenitis Suppurativa COSENTYX is indicated for...
Mechanism: Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2026 Supplement 13 · Efficacy LetterLabelMedication Guide
- Oct 6, 2023 Original approval · Type 3 - New Dosage Form LetterLabelReview
1 products under this application
- COSENTYX · SECUKINUMAB 150MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Secukinumab" as an intervention, any sponsor and status, largest first.
- Plaque Psoriasis Efficacy and Safety With SecukinumabPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02409667 · 16,487 participants · Start May 7, 2015 · Primary completion Mar 14, 2017
Drug: Secukinumab · For: Plaque Psoriasis
Sites: Innsbruck, Austria; Linz, Austria; Vienna, Austria · 200 sites in all
- A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)Pivotal-lookingTerminated
Eli Lilly and CompanyEli Lilly (LLY)
NCT03556202 · 1,936 participants · Start Sep 3, 2018 · Primary completion Feb 7, 2022
Drug: Mirikizumab · For: Psoriasis
Sites: Birmingham, Alabama; Beverly Hills, California; Encinitas, California · 229 sites in all
- A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.Completed
Novartis PharmaceuticalsNovartis (NVS)
NCT02752776 · 1,660 participants · Start Mar 17, 2016 · Primary completion Mar 28, 2018
Drug: Secukinumab · For: Plaque Psoriasis
Sites: Geel, Belgium; Bruges, Belgium; Ghent, Belgium · 215 sites in all
- A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03535194 · 1,484 participants · Start Jun 26, 2018 · Primary completion Mar 5, 2020
Drug: Mirikizumab; Placebo and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; Bakersfield, California; Beverly Hills, California · 178 sites in all
- Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type PsoriasisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01358578 · 1,306 participants · Start Jun 2011 · Primary completion Jul 2013
Drug: Placebo; secukinumab (AIN457) and 1 more · For: Chronic Plaque Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 152 sites in all
- Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With SecukinumabPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01544595 · 1,147 participants · Start Jun 19, 2012 · Primary completion Jun 26, 2017
Drug: Secukinumab (AIN457); Placebo · For: Moderate to Severe Plaque-type Psoriasis
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 182 sites in all
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque PsoriasisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02826603 · 1,114 participants · Start Jun 22, 2016 · Primary completion Jul 9, 2018
Drug: Secukinumab; Ustekinumab · For: Plaque Psoriasis
Sites: Anniston, Alabama; Birmingham, Alabama; Mobile, Alabama · 154 sites in all
- A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03090100 · 1,048 participants · Start Apr 27, 2017 · Primary completion Aug 2, 2018
Drug: Guselkumab; Placebo and 1 more · For: Psoriasis
Sites: Birmingham, Alabama; Los Angeles, California; Oceanside, California · 142 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective29,381
- psoriasis22,918
- pain16,854
- arthralgia15,102
- fatigue10,786
- psoriatic arthropathy10,387
- malaise9,598
- pruritus9,542
- rash9,297
- condition aggravated8,697
- diarrhoea8,168
- nasopharyngitis7,955
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 11 |
| 2015 | 2,812 |
| 2016 | 6,260 |
| 2017 | 11,695 |
| 2018 | 20,874 |
| 2019 | 21,465 |
| 2020 | 22,595 |
| 2021 | 17,026 |
| 2022 | 17,155 |
| 2023 | 17,264 |
| 2024 | 11,057 |
| 2025 | 9,204 |
| 2026 | 4,482 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cosentyx (Secukinumab)
2024 spending
$1.1M
Beneficiaries
60
258 claims
Per beneficiary
$18,892
$418.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,133,519 |
Part B: Cosentyx (Secukinumab) · HCPCS J3247
2024 spending
$54.2M
Beneficiaries
3,236
12,224 claims
Per beneficiary
$16,757
2024 ASP limit $17.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $54,225,555 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K, Warren RB, Lebwohl M, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.
Stone JH, Buttgereit F, Saraux A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.